Immunosuppressants against acute kidney injury: what to prefer or to avoid?

Simple item page
dc.contributor.authorGaikwad, Anil Bhanudas
dc.date.accessioned2025-03-17T10:20:05Z
dc.date.available2025-03-17T10:20:05Z
dc.date.issued2024-03
dc.description.abstractAcute kidney injury (AKI) is a critical global health issue associated with high mortality rates, particularly in patients undergoing renal transplants and major surgeries. These individuals often receive immunosuppressants to dampen immune responses, but the impact of these drugs on AKI remains unclear.en_US
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/08923973.2024.2330641
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18391
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.subjectPharmacyen_US
dc.subjectImmune systemen_US
dc.subjectImmunosuppressanten_US
dc.subjectAcute kidney injury (AKI)en_US
dc.subjectImmune checkpoint inhibitorsen_US
dc.subjectMonoclonal antibodiesen_US
dc.titleImmunosuppressants against acute kidney injury: what to prefer or to avoid?en_US
dc.typeArticleen_US

Files

Collections

Department of Pharmacy